English
This article is from The Journal of Biological Chemistry , volume 288 . Abstract Background: Secreted PCSK9 regulates LDL levels in plasma by mediating degradation of hepatic LDL receptors.Results: LDL binds to PCSK9 in human plasma and in vitro and inhibits PCSK9 binding to cell surface LDL receptors.Conclusion: A large proportion of circulating PCSK9 is bound to LDL in humans.Significance: Regulatory mechanisms that affect activity of secreted PCSK9 represent novel targets for cholesterol-lowering therapies.
Sign in with your free account to read, download EPUBs or listen.
Ebook · Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation*. · Kosenko, Tanja, Golder, Mia, Leblond, Geoffrey, Weng, Willy, Lagace, Thomas A. · Internet Archive